LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study

作者：Chengcheng Zhou, Yidan Lu, S-W. Kim, T. Baisamut, Jianhui Zhou, Y. Zhang, J. He, Junpei Yang, Yufeng Cheng, SH Lee, J. Chang, J. Fang, Z. Liu, L. Bu, L. Qian, T. Xu, V. Archer, M. Hilton, M. Zhou, L. Zhang · 发表于：Annals of Oncology · 年份：2022 · DOI：10.1016/j.annonc.2022.10.353 · 被引用次数：20 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Lung Cancer Research Studies